Počet záznamov: 1
receptor erbB-2
SYS d018719 LBL 00000cz--a2200000n--4500 005 20250606214155.4 008 991104|||anznnbabn-----------|-a|a------ 040 $b slo $a DNLM $d BA006 $d BA006 $d BA006 065 $a D08.811.913.696.620.682.725.400.009.400 065 $a D12.776.476.568.400.009.400 065 $a D12.776.543.750.630.009.400 065 $a D12.776.543.750.750.400.074.400 065 $a D12.776.624.664.700.642 065 $a D23.050.301.500.600.700 065 $a D23.050.705.552.600.550 065 $a D23.101.140.642 066 $a 01 $c 03 150 $a receptor erbB-2 $x AD $x AG $x AI $x AN $x BI $x BL $x CH $x CL $x DE $x DF $x GE $x HI $x IM $x IP $x ME $x PH $x RE $x TU $x UL $2 slo 450 $w v $a c-erbB-2 Protein $2 eng 450 $w v $a erbB-2 Proto-Oncogene Protein $2 eng 450 $w v $a erbB-2 Receptor Protein-Tyrosine Kinase $2 eng 450 $w v $a HER-2 Proto-Oncogene Protein $2 eng 450 $w v $a neu Proto-Oncogene Protein $2 eng 450 $w v $a Proto-Oncogene Protein HER-2 $2 eng 450 $w v $a Proto-Oncogene Protein p185(neu) $2 eng 450 $w v $a proteín c-erbB-2 $2 slo 450 $w v $a proteín protoonkogénový erbB-2 $2 slo 450 $w v $a receptor tyrozínovej proteínkinázy erbB-2 $2 slo 450 $w v $a receptor proteín-tyrozínkinázy erbB-2 $2 slo 450 $w v $a receptor tyrozín kináz erb-b2 $2 slo 450 $w v $a proteín protoonkogénový neu $2 slo 450 $w v $a receptor neu $2 slo 450 $w v $a proteín protoonkogénový HER-2 $2 slo 450 $w v $a proteín protoonkogénový p185(neu) $2 slo 450 $w v $a antigény CD340 $2 slo 450 $w v $a p185 (c-neu) $2 slo 450 $w v $a proteín p185erbB2 $2 slo 550 $7 sllk_us_auth*d018734 $Y Genes, erbB-2 $w p $a gény erbB-2 550 $7 sllk_us_auth*d000068878 $Y Trastuzumab $w p $a trastuzumab 550 $7 sllk_us_auth*d018734 $Y Genes, erbB-2 $w b $a gény erbB-2 550 $7 sllk_us_auth*d020880 $Y Neuregulins $w b $a neuregulíny 550 $7 sllk_us_auth*d000068878 $Y Trastuzumab $w b $a trastuzumab 665 $a 2019 (1995) $2 eng 665 $a Epidermal Growth Factor Receptor Protein-Tyrosine Kinase (1994) $2 eng 665 $a Phosphoproteins (1985) $2 eng 665 $a Proto-Oncogene Proteins (1986-1994) $2 eng 680 9-
$i A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member. $2 eng 750 -2
$a Receptor, ErbB-2 $2 eng 980 $x M
Počet záznamov: 1